[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354984-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354984-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","efficacy-and-safety-of-epidermal-radionuclide-therapy-with-188re-resin-in-patients-with-nonmelanoma-skin-cancers-long-term-data-from-a-single-center","Efficacy and Safety of Epidermal Radionuclide Therapy with 188Re Resin in Patients with Nonmelanoma Skin Cancers - Long-Term Data from a Single Center","","Nonmelanoma skin cancer in elderly patients is often treated surgically, but inoperable cases require effective alternatives. This single-center study assessed 188Re epidermal radionuclide therapy (188Re-ERT) for local control, enrolling 124 consecutive patients with 181 histologically confirmed lesions. Efficacy was evaluated via videodermoscopy and biopsy up to 36 months, with relapses confirmed histologically. Outcomes showed a 91.1% 36-month relapse-free rate, while larger lesion size significantly increased relapse risk. Adverse skin reactions were predominantly mild (G1–G2), resolving within a mean 32 days, supporting safety and effectiveness.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/efficacy-and-safety-of-epidermal-radionuclide-therapy-with-188re-resin-in-patients-with-nonmelanoma-skin-cancers-long-term-data-from-a-single-center/354984/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/efficacy-and-safety-of-epidermal-radionuclide-therapy-with-188re-resin-in-patients-with-nonmelanoma-skin-cancers-long-term-data-from-a-single-center/354984.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Who was included in the 188Re-ERT study and how many lesions were treated?","Question",{"text":63,"@type":64},"The study included 124 consecutive patients (79 men, 45 women) with histologically confirmed nonmelanoma skin cancer. A total of 181 lesions were treated.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was efficacy measured, and what was the 36-month relapse-free rate?",{"text":68,"@type":64},"Efficacy was evaluated 6 months after treatment and followed at 12, 18, 24, and 36 months using videodermoscopy and biopsy, with relapses confirmed histologically. The overall relapse-free rate at 36 months was 91.1% (165 of 181 lesions).",{"name":70,"@type":61,"acceptedAnswer":71},"What adverse reactions occurred and how quickly did they resolve?",{"text":72,"@type":64},"Most early adverse skin reactions were classified as G1 or G2 and resolved within a mean time of 32 days. G3 reactions occurred in 16 lesions and lasted up to 8–12 weeks, generally without reported pain during or after treatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354984,1790473956,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Efficacy and Safety of Epidermal Radionuclide Therapy with 188Re Resin in Patients with Nonmelanoma Skin Cancers:  \nLong-Term Data from a Single Center  \nPaolo Castellucci 1, Carlotta Baraldi2, Luigia Vetrone 1, Federico Zagni3, Claudio Malizia 1, Alessio Giuseppe Morganti4,5, Lidia Strigari3, Emi Dika2,5, and Stefano Fanti 1,5  \n1Nuclear Medicine IRCCSAzienda Ospedaliero-Universitaria S.Orsola, Bologna, Italy; 2Oncologic Dermatology Unit, IRCCSAzienda Ospedaliero-Universitaria S.Orsola, Bologna, Italy; 3Department of Medical Physics, IRCCSAzienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 4Radiation Oncology IRCCSAzienda Ospedaliero-Universitaria S.Orsola, Bologna, Italy; and 5Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy  \nNonmelanoma skin cancer (NMSC) occurs in photoexposed areas and is frequent in the elderly population. Surgical excision remains the treatment of choice whenever feasible. However, alternative approaches are clinically important for patients who are unsuitable for surgery. This study evaluated the efﬁcacy and safety of 188Re epidermal radionuclide therapy (188Re-ERT) for local disease control in NMSCs deemed inoperable. Methods: In total, 124 consecutive patients (79 men, 45 women; mean age, 81 y [range, 49–94 y]) with histologic conﬁrmation of NMSC were treated with 188Re-ERT, with 181 lesions treated. Efﬁcacy was evaluated 6 mo after 188Re-ERT with videodermoscopy and biopsy. Follow-up was performed at 12, 18, 24, and 36 mo. Relapses were conﬁrmed histologically. Safety was assessed on the basis of CTCAE version 5.0. Results: Lesion characteristics included surface area (mean, 6.0 cm2; range, 1–34 cm2), thickness (mean, 1.2 mm; range, 0 .2–3.0 mm), volume (mean, 0 .85 cm3; range, 0 .05–7.7 cm3) . Locations include the H area (102 lesions), scalp (39 lesions), extremities (24 lesions), and thorax (16 lesions) . Histology conﬁrmed 104 basal cell carcinoma; 71 squamous cell carcinoma, and 6 basosquamous carcinoma. Mean administered dose to the lesion was 51 Gy, the mean dose to the deepest point of cancer invasion was 25 Gy, and the mean treatment duration was 90 min. No patient reported pain during or after the treatment. Overall, 165 of 181 lesions (91 . 1%) were relapse-free at 36 mo. Relapses occurred in16patients as follows: 6 at 6 mo, 3at 12mo, 2at 18 mo, 3 at 24 mo, and 2 at 36 mo. Lesions less than 8 cm2 demonstrated a relapse rate of 1.4% at 6 mo. Larger lesion area volumes were signiﬁcantly associated with relapse. Early adverse skin reactions classiﬁed according to CTCAE version as G1 (minimal skin changes, fainterythema, or dry desquamation) or G2 (moderate erythema, patchy moist desquamation, and edema) were observed in 165 of 181 lesions (91.1%) and resolved within a mean time of 32 d; G3 skin reactions (severe skin changes without pain) were present in 16 lesions, lasting up to 8–12 wk. Conclusion: 188Re-ERT showed high efﬁcacy with arelapse-free rate of 91.1% at 36 mo. Larger lesions were associated with an increased risk of relapse. Adverse events were generally mild, resolving within 32 d. These results support 188Re-ERT as a safe and effective alternative for patients with inoperable NMSC.  \nReceived May 8, 2025; revision accepted Sep. 4, 2025 .  \nFor correspondence, contact Luigia Vetrone ([luigia.vetrone@studio.unibo.it](luigia.vetrone@studio.unibo.it)). Published online Nov. 20, 2025 .  \nImmediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: [https://creativecommons](https://creativecommons).  \norg/licenses/by/4.0/. Details: [https://jnm.snmjournals.org/page/permissions](https://jnm.snmjournals.org/page/permissions). COPYRIGHT 􀀁 2026 by the Society of Nuclear Medicine and Molecular Imaging.  \nKey Words: nonmelanoma skin cancer; epidermal radionuclide therapy; 188Re; ","cbCaiqxDELdiaYxm","https://ap.wps.com/l/cbCaiqxDELdiaYxm","pdf",987265,"English","# Methods\n## Patient cohort and lesion assessment\n## Efficacy evaluation\n## Safety assessment\n# Results\n## Lesion characteristics\n## Relapse-free outcomes\n## Adverse skin reactions\n# Conclusion","[{\"question\":\"Who was included in the 188Re-ERT study and how many lesions were treated?\",\"answer\":\"The study included 124 consecutive patients (79 men, 45 women) with histologically confirmed nonmelanoma skin cancer. A total of 181 lesions were treated.\"},{\"question\":\"How was efficacy measured, and what was the 36-month relapse-free rate?\",\"answer\":\"Efficacy was evaluated 6 months after treatment and followed at 12, 18, 24, and 36 months using videodermoscopy and biopsy, with relapses confirmed histologically. The overall relapse-free rate at 36 months was 91.1% (165 of 181 lesions).\"},{\"question\":\"What adverse reactions occurred and how quickly did they resolve?\",\"answer\":\"Most early adverse skin reactions were classified as G1 or G2 and resolved within a mean time of 32 days. G3 reactions occurred in 16 lesions and lasted up to 8–12 weeks, generally without reported pain during or after treatment.\"}]","Efficacy and Safety of Epidermal Radionuclide Therapy with 188Re Resin in Patients with Nonmelanoma Skin Cancers - Long-Term Data from a Single Center | PDF",1790115236,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fba3cfb6dd0f44629642c093634c8465.webp",983,1296,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f461dcea8d7a78a3c4c0322f743b5937.webp",982,1294,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e81a9d4619c26ecd131693147125eae.webp",981,1293,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d47fc56c745dafb9bb9e7b485cd0df85.webp",980,1292]